Abstract: Compounds including a tetrapyrrolic or reduced tetrapyrrolic group/moiety and an epidermal growth factor receptor targeting group are disclosed. For example, a compound includes a tetrapyrrolic or reduced tetrapyrrolic group or moiety, a linker moiety, an epidermal growth factor receptor targeting group, and, optionally, a PET-active functional group. Uses of the compounds, for example, methods of treating a hyperproliferative tissue in an individual, and kits including one or more of the compounds are also provided.

Abstract: New advantageous compositions and methods for treatment of malignancies such as basel cell carcinoma and other skin cancers, brain tumors, head and neck cancer, kidney cancer, prostate cancer and other cancer types. The new compositions and methods may also be used for treatment of non-cancer problems such as dermatological diseases, sexual diseases, anti-fungal and antibacterial and wound healing. A new photodynamic therapy/sonodynamic therapy (PDT/SDT) combination approach using near infrared (NIR) tetrapyrrolic photosensitizers (PSs) with long wavelength absorption, in the range of 750-800 nm, that provides deeper tissue penetration. Such combinations may be postloaded onto PAA nanoparticles (NPs) for better delivery to a tumor site. A preferred sonodynamic compound is fullerene 60 but other sonodynamic compounds may be employed. The unique NP formulations of the invention can contain chemotherapeutic agents releasable by ultrasound in cancer or other hyperproliferative tissue.

Abstract: The present disclosure provides compounds comprising a tetrapyrrole (e.g., a tetrapyrrole group) linked via a linker to one or more ligands and uses of the compounds. The compounds may be used as imaging agents (e.g., MRI contrast agents) or as both imaging and therapeutic agents. The compounds may be used to treat individuals in need of treatment for a hyperproliferative disorder, such as, for example, malignancy. The present disclosure also provides kits comprising pharmaceutical preparations containing any one or any combination of the compounds described herein.

Abstract: Methods for treatment of cancer are provided. The methods are based on the use of both NIR photosensitizer(s) and chemotherapy agent(s). The NIR photosensitizers have a tetrapyrrolic core or reduced tetrapyrrolic core. Also provided are pharmaceutical compositions comprising NIR photosensitizer(s) and chemotherapy agent(s). Also provided are kits comprising NIR photosensitizer(s) and chemotherapy agent(s) and instructions for their use.

Abstract: Compounds including a tetrapyrrolic or reduced tetrapyrrolic group/moiety and an epidermal growth factor receptor targeting group are disclosed. For example, a compound includes a tetrapyrrolic or reduced tetrapyrrolic group or moiety, a linker moiety, an epidermal growth factor receptor targeting group, and, optionally, a PET-active functional group. Uses of the compounds, for example, methods of treating a hyperproliferative tissue in an individual, and kits including one or more of the compounds are also provided.

Abstract: The present invention discloses a method for reducing alopecia and bladder toxicity associated with the anti-cancer agent cyclophosphamide. The method comprises administering to an individual, in need of such a treatment, cyclophosphamide and a selenium compound. The selenium compounds may be administered before, during or after administration of the anti-cancer agent.

Abstract: A method for augmenting the antitumor activity of anti-cancer agents is provided. The method comprises administering to an individual an anti-cancer and a selenium compound. A method is also provided for inhibiting the growth of a tumor which-has proven to be refractory to anticancer agents. The methods comprises administration of selenium compound followed by administration of the anticancer agent.

Abstract: The present invention discloses a method for enhancing the efficacy of anti-cancer agents. The method comprises administering to an individual, in need of such a treatment, an anti-cancer agent and a selenium compound. The selenium compounds may be administered before, during or after administration of the anti-cancer agent.

Abstract: A method for augmenting the antitumor activity of anti-cancer agents is provided. The method comprises administering to an individual an anti-cancer agent and a selenium compound. The selenium compounds may be administered before, during or after administration of the anti-cancer agent.

Abstract: The present invention discloses a method for reducing the toxicity of anti-cancer agents oxaliplatin and doxorubicin. The method comprises administering to an individual, in need of such a treatment, the anti-cancer agent and a selenium compound. The selenium compounds may be administered before, during or after administration of the anti-cancer agent.

Abstract: The present invention discloses a method for enhancing the efficacy of anti-cancer agents. The method comprises administering to an individual, in need of such a treatment, an anti-cancer agent and a selenium compound. The selenium compounds may be administered before, during or after administration of the anti-cancer agent.